Venugopal P
Recent Posts
Reversal of low loop...
14 Dec 2023 01:51:44 AMSuspensory ligament ...
09 Jun 2023 09:03:07 AMCould the bulbar ure...
07 Jun 2023 12:26:00 PMSpotter
19 Mar 2023 09:18:09 PMA case: Diagnosis & ...
10 Mar 2023 08:34:24 AMAUA Guideline Management of LUTS/BPH Part 1 and 2
Dear All,
In recent
Years, there have been many advances in the Surgical Treatments for LUTS/BPH,
which has made AUA to look into this with a series of Amendments, both in 2019
and 2020. Both these Amendments addressed only the Surgical Managements.
The 2019
Amendment was authored by Harris E Foster* et al.
https://www.auajournals.org/doi/pdf/10.1097/JU.0000000000000319
Based on
this Amendment, Ryan Dornbier*, Kevin T McVary et al (2020) brought out ‘The
New American Urological Association Benign Prostatic Hyperplasia Clinical
Guidelines: 2019 Update’ which is a good read to understand, reiterating most
of what has been provided in the AUA 2019.
https://link.springer.com/content/pdf/10.1007/s11934-020-00985-0.pdf
Advances
in our understanding using the Newer Options occurred rapidly necessitating a relook
at the Surgical Management of LUTS/BPH and this 2020 amendment was authored by J
Kellogg Parsons* et al.
https://www.auajournals.org/doi/pdf/10.1097/JU.0000000000001298
Advances
in most aspects on our understanding of LUTS/BPH necessitated AUA to bring out
a New Guideline for LUTS/BPH. The
AUA announced on August 16th 2021, its new updates to its clinical guideline
on the management of LUTS attributed to BPH. The updates within this guideline aim to further support urologists in
the effective, evidence-based management of male LUTS/BPH. This has been
brought, published online on Aug 13th in two sections. The Guideline
Panel was headed by Lori B Lerner* et al. The section 2 is based
on ‘Surgical Evaluation and Treatment’ which is mostly a revised version of the
previous amendments provided. A new section was added wherein new Evaluations
and Preoperative testing statements have been recommended and this new section
added on the medical management of BPH to
include guidance on alpha blockers, 5-ARIs, PDE5s, combination therapy and
acute urinary retention outcomes.
Section 1:
https://www.auajournals.org/doi/pdf/10.1097/JU.0000000000002183
Section 2:
https://www.auajournals.org/doi/pdf/10.1097/JU.0000000000002184
If all the materials
provided, when read together, will help us understand most aspects on LUT/BPH
from the AUA Point of view.
With warm Regards,
Venu
You want to add your comment? Please login